Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-613 and 5-FU in Metastatic Colorectal Cancer
NCT02232152Phase 1Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jan 2015
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of devimistat in colorectal cancer (CRC), sponsored by Wake Forest University Health Sciences. Primary endpoint: Maximum Tolerated Dose at 2 weeks. Started Jan 2015; status: completed.
02
Drugs
devimistat
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02232152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02232152.